Repligen Corporation to Present at Barclays Global Healthcare Conference
Repligen Corporation (NASDAQ:RGEN) will present at the Barclays Global Healthcare Conference from March 9-11, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Repligen Corporation (NASDAQ:RGEN) will present at the Barclays Global Healthcare Conference from March 9-11, 2021. CFO Jon Snodgres is scheduled for a fireside chat on March 10 at 1:50 p.m. EST. A live webcast of this discussion will be available on the Company’s Investor Relations website and will be accessible for replay afterwards. Repligen specializes in innovative bioprocessing technologies for the biopharmaceutical industry, enhancing drug manufacturing efficiency globally.
Details
News Market Reaction – RGEN
The recorded move for RGEN in the trading session of this news was -6.01%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the Barclays Global Healthcare Conference being held March 9-11. Jon Snodgres, Chief Financial Officer, will participate in a fireside chat on Wednesday, March 10, at 1:50 p.m. EST.
A live webcast of the discussion will be accessible through the Investor Relations section of the Company’s website, and will be available for replay for a limited period of time following the conference event.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. Our primary customers are biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located within the U.S. (California, Massachusetts, New Jersey and New York), and outside of the U.S. we have sites in Estonia, Germany, Ireland, the Netherlands and Sweden.
Repligen Contact:
Sondra S. Newman
Global Head of Investor Relations
(781) 419-1881
investors@repligen.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.